GEN Exclusives

More »

GEN News Highlights

More »
Oct 15, 2012

STA Licenses Cancer Cachexia Drug

  • Swiss pharma firm Helsinn granted Specialised Therapeutics Australia (STA) exclusive commercialization rights in Australia and New Zealand to its Phase III-stage ghrelin receptor agonist, anamorelin, for the treatment of non-small cell lung cancer cachexia-anorexia.

    STA has already successfully commercialized Helsinn’s 5-HT3 antagonist Aloxi® (palonosetron), and holds a license to the firm’s Phase III-stage fixed dose netupitant-palonosetron combination therapy for preventing chemotherapy-induced nausea and vomiting. Under terms of the latest anamorelin deal, STA will be responsible for regulatory/clinical development and commercial activities within Australia and New Zealand.

    There are currently no approved therapies for treating muscle wasting and more generally cachexia-anorexia in cancer patients, the firms note. Helsinn’s anamorelin is currently undergoing two Phase III trials, Romana 1 and Romana 2, as at treatment for cachexia-anorexia in patients with NSCLC. The two studies will enroll about 477 patients in over 15 countries, and patients who complete Romana 1 or Romana 2 and opt to continue on anamorelin therapy will be enrolled into an extension safety study, Romana 3. Pending positive trial results, an NDA filing with FDA is anticipated in mid-2014, followed immediately by regulatory filing in Australia. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?